 YANTAI, China, Jan. 20, 2023 PRNewswire RemeGen Co., Ltd. RemeGen or the Company 9995.HK, SHA: 688331, a commercial-stage biotechnology company, is pleased to announce that as of January 18, 2023, two indications for the Companys proprietary anti-HER2 antibody-drug conjugate ADC, Disitamab Vedotin RC48, have been successfully included in the new version of national reimbursement drug list NRDL ...... 